Restylane® Skinboosters™ Vital in the décolletage Region

Inclusion Criteria: 1. A score \> 2 on the GDS, as assessed by the treating physician at Baseline. 2. Females aged \> 25 and \< 70 3. Ability to adequately understand the verbal explanations and the written subject information provided in local language and ability and willingness to give consent to participate in the study. 4. Signed and dated informed consent to participate in the study and unrestricted use of décolletage images for marketing purpose. 5. If female of childbearing potential: a negative urine pregnancy test before all treatments is required. Exclusion Criteria: 1. Current Pregnancy or lactation \[sexually active women of childbearing age must agree to use medically acceptable methods of contraception for the duration of this study (e.g., oral contraceptives, condoms, intrauterine device, shot/injection, patch)\]; 2. Patients meeting any official Restylane contra-indications; 3. Inability to comply with follow-up and abstain from other treatments in the region of interest during the study period; 4. Heavy smokers, classified as smoking more than 12 cigarettes per day; 5. History of severe or multiple allergies manifested by anaphylaxis; 6. Previous tissue revitalization therapy in the treatment area within 6 months before treatment with laser or light, mesotherapy, radiofrequency, ultrasound, cryotherapy, chemical peeling, or dermabrasion; 7. Subjects presenting with known allergy to hyaluronic acid (HA) filler or amide local anesthetics. 8. Subjects presenting with porphyria. 9. Subjects with active disease, such as inflammation, infection or tumors, in or near the intended treatment site. 10. Subjects with bleeding disorders or in subjects who are taking thrombolytics or anticoagulants. 11. Subjects using immunosuppressants. 12. History of other décolletage treatment/procedure in the previous 6 months below the level of the neck that, in the treating investigator's opinion, would interfere with the study injections and/or study assessments or exposes the subject to undue risk by study participation. 13. Tattoos, piercings or visible markings that in the treating investigator's opinion, may interfere with results or assessments \[excessive sun damage, tan lines, dark spots, moles, scars (hypertrophic, keloid), tan lines\]. 14. Cancer or precancer in the treatment area, e.g. actinic keratosis; 15. History of bleeding disorders or treatment with thrombolytics, anticoagulants, or inhibitors of platelet aggregation (e.g. Aspirin or other non-steroid anti-inflammatory drugs \[NSAIDs\]), within 2 weeks before treatment; 16. Patients using immunosuppressants; 17. Patients with a tendency to form hypertrophic scars or any other healing disorders; 18. Patients with known hypersensitivity to lidocaine or agents structurally related to amide type local anesthetics (e.g., certain anti-arrhythmics); 19. Patients with epilepsy, impaired cardiac conduction, severely impaired hepatic function or severe renal dysfunction.